<DOC>
	<DOCNO>NCT02935608</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy two dose regimen BIIB074 neuropathic pain participant pain lumbosacral radiculopathy ( PLSR ) . Secondary objective evaluate efficacy 2 dose regimen BIIB074 additional neuropathic pain measure assessment low back pain , disability , quality life ; To investigate safety tolerability 2 dose regimen BIIB074 To characterize pharmacokinetics ( PK ) BIIB074 population .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety BIIB074 Neuropathic Pain From Lumbosacral Radiculopathy</brief_title>
	<detailed_description>Convergence Pharmaceuticals , Ltd. , register England , acquire affiliate subsidiary Biogen , Inc .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<criteria>Key Has body weight ≥50 kg men ≥45 kg woman Must diagnosis neuropathic PLSR Has duration neuropathic ( leg ) pain least 6 month Screening Has intensity ≥4 ≤9 Numerical Rating Scale base paperbased question Screening Day 1 asks average pain intensity neuropathic ( leg ) pain due PLSR last week Key Has plan surgical intervention PLSR within duration study . ( Subjects persistent radicular pain prior surgery eligible . ) Has history peripheral neuropathy ( e.g. , due diabetes , alcohol consumption , cause , idiopathic ) evidence peripheral neuropathy upon neurological examination Has history risk seizures history epilepsy , clinically significant head injury , related neurological disorder NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>